

Remarks

With the present preliminary amendment, the title has been amended to more accurately reflect the claimed invention. Original claims 1-23 have been canceled without prejudice or disclaimer. Applicants reserve the right to pursue the canceled subject matter in continuing applications. New claims 24-63 (encompassing Gene No. 18 polypeptides) have been added to assist in expediting prosecution of the present application. Hence, new claims 24-63 are currently pending in the present application.

Support for new claims 24-63 can be found throughout the present application and claims as originally filed. In particular, support for new claims 24-63 can be found, for example, in the specification at: page 74, last row in Table 1 for disclosure of Gene No. 18 describing the HBIMF63 ATCC Deposit; SEQ ID NO:47 (full length) amino acids 1-105, SEQ ID NO:47 (secreted) amino acids 24-105); pages 86-88 (secreted portion); pages 89, line 9 to page 93, line 3 (90% and 95% identity); page 98, lines 2-3 (30 and 50 contiguous amino acids); page 99, lines 17 and 20 and page 128, line 5 to the bottom of page 129 (ELISA and Western Blots); page 106, lines 12-19 (antibody binding); page 331 (Example 23) (compositions); page 102, line 27 to page 104 and page 306 (Example 9) (heterologous polypeptides); page 149, lines 15-29 (complete polypeptide minus methionine); page 149, lines 8-14 and page 152, lines 3-27 (isolated protein produced by the method and inherent post-translational modifications therein) and, pages 298-306 (Examples 5-8) (polypeptide production). Thus, no new matter has been introduced and entry of new claims 24-63 is respectfully requested.


Applicants respectfully note that the elected polypeptide, Gene No. 18, is primarily expressed in ovary cancer (Grade II papillary carcinoma) (see page 70, lines 16-17 of the present specification). Therefore, the claimed invention is useful as a diagnostic marker for such ovary cancer, as discussed on page 71, lines 21-22 of the present specification.

Conclusion

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Date: July 11, 2002


Janet M. Martineau (Reg. No. 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (telephone)

KKH/JMM/rmr

VERSION TO SHOW CHANGES MADE

In the Specification:

On page 1, line 1, the title was replaced with the following new title:

—Secreted Protein HBIMF63—

In The Claims:

Claims 1-23 have been canceled without prejudice or disclaimer.

New claims 24-63 were added.